Company news
Aclarion, Inc. (NASDAQ:ACON) news
Aclarion, Inc. news releases on 6ix. Latest, May 5, 2025: Aclarion Welcomes Advocate Health as CLARITY Trial Site
Press releases — page 2
Aclarion Welcomes Advocate Health as CLARITY Trial Site
May 5, 2025
Aclarion Announces Commercial Agreement with Spine Institute of Louisiana
April 29, 2025
Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025
April 23, 2025
Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis
April 21, 2025
Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub
April 9, 2025
Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California
April 2, 2025
Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives
March 31, 2025
Aclarion Announces Reverse Stock Split
March 26, 2025
Aclarion Provides Shareholder Update
March 13, 2025
Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey
March 6, 2025
Aclarion Announces First Commercial Agreement with Scripps Health
March 3, 2025
Aclarion, Inc. Announces Adjournment of Special Meeting of Stockholders
February 28, 2025
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit
February 20, 2025
Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body
February 10, 2025
Aclarion Announces Northwestern Medicine as First CLARITY Trial Site
February 5, 2025
Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded
February 3, 2025
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference
January 30, 2025
Aclarion Announces Pricing of Registered Direct Offering of Common Stock Priced at the Market
January 29, 2025
Aclarion Announces Revised Split Ratio and Timing for Reverse Stock Split
January 27, 2025
Aclarion Announces Closing of $14.4 Million Public Offering of Common Stock and Warrants
January 16, 2025
Aclarion Announces Pricing of $14.4 Million Public Offering of Common Stock and Warrants
January 14, 2025
Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash
November 20, 2024
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
September 26, 2024
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones
September 11, 2024
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
September 9, 2024
Aclarion Added to PRISM Emerging Medical Devices Index
September 5, 2024
Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market
September 4, 2024
Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey
August 28, 2024
Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans
August 20, 2024
Aclarion Announces First Commercial Agreement in Michigan
August 13, 2024
Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
August 12, 2024
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
July 8, 2024
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
June 25, 2024
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London
June 24, 2024
Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution
June 19, 2024
Aclarion Announces Updated Product Release That Enhances User-Experience, Scalability, and Security for Nociscan Solution
June 17, 2024
Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain
April 24, 2024
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
March 3, 2024
Aclarion Announces Closing of $3.0 Million Public Offering
February 26, 2024
Aclarion Announces Pricing of $3.0 Million Public Offering
February 25, 2024
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
February 4, 2024
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
January 21, 2024
Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution
January 16, 2024
Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan
January 7, 2024
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
November 26, 2023
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
November 7, 2023
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
November 5, 2023
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
October 24, 2023
Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
October 23, 2023
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
October 22, 2023